Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 321

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

The Effectiveness and Relative Effectiveness of Intravenous Inotropic Drugs Acting Through the Adrenergic Pathway in Patients with Heart Failure—A Meta-Regression Analysis

Open access
Thackray, Simon, Easthaugh, Joanne, Freemantle, Nick, Cleland, John G.F.·2002·European Journal of Heart Failure

Abstract

Aims: To review systematically the use of intravenous (IV) inotropic agents acting through the adrenergic signalling pathway, compared with placebo or an active agent, in patients with heart failure. Methods: Studies investigating the use of intravenous inotropes in patients with heart failure published between 1966 and 2000 were identified using MEDLINE, the Cochrane register and Embase databases. Reference lists from relevant papers and reviews were hand searched for further papers. In total, 21 trials, that included 632 patients receiving IV inotropic drugs, placebo or non-treatment control, were identified. Drugs of the following classes were included, the β-agonists; dobutamine, high-dose (>2.5 μg/kg/min) dopamine, dopexamine and the phosphodiesterase (PDE) inhibitors; amrinone, milrinone, enoximone and toborinone. Sixteen trials (474 patients) contributed data from acute invasive haemodynamic studies of symptomatically severe heart failure. Five trials (158 patients) were based on intermittent inotropic therapy in an outpatient context. Results: With few exceptions, trials of intravenous inotropic agents were small and often failed to report clinically important outcomes. Compared to placebo, intravenous inotropic agents acting through the adrenergic system tended to increase mortality (odds ratio 1.50 (95% CI-0.51 to 3.92) but this did not reach significance and insufficient data were available to determine whether symptoms improved. There appeared to be little difference in the effect of beta-agonists compared to PDE inhibitors on patient outcomes but this could be attributed to the paucity of data. Conclusions: Intravenous inotropic agents acting through the adrenergic pathway are often used in patients with worsening heart failure to achieve arbitrary haemodynamic targets. Our analyses show that there is very little evidence that such treatment improves symptoms or patient outcomes and may not be safe. This highlights the need for further well designed randomised clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1388-9842(02)00041-7

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 321

Metadata

Authors
Thackray, S., Easthaugh, J., Freemantle, N., & Cleland, J. G. F.
Venue
European Journal of Heart Failure
Published
2002-08-01
Volume
4
Issue
4
Pages
515-529
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W2153334293
Cited by
321
References
4
FWCI
8.10
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Effectiveness and Relative Effectiveness of Intravenous Inotropic Drugs Acting Through the Adrenergic Pathway in Patients with Heart Failure—A Meta-Regression Analysis. https://app.cochat.ai/papers/10.1016/s1388-9842(02)00041-7
The paper
Thackray, S., Easthaugh, J., Freemantle, N., & Cleland, J. G. F. (2002). The Effectiveness and Relative Effectiveness of Intravenous Inotropic Drugs Acting Through the Adrenergic Pathway in Patients with Heart Failure—A Meta-Regression Analysis. European Journal of Heart Failure. https://doi.org/10.1016/s1388-9842(02)00041-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.